menu search

Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy<...

June 10, 2023, 2:47 pm

Why shares of day one pharmaceuticals are up monday

Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive p...

June 5, 2023, 12:30 pm

Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)

– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% ...

June 3, 2023, 6:15 pm

Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a

– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pha...

May 25, 2023, 9:15 pm

Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a

– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pha...

May 25, 2023, 9:15 pm

Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...

May 25, 2023, 5:15 pm

Shattuck labs to present complete dose-escalation data from phase 1a monotherapy clinical trial of sl-172154 in platinum-resistant ovarian cancer (proc) at the american society of clinical oncology (a

- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharm...

May 25, 2023, 5:15 pm

Molecular partners to present positive data from ongoing phase 1 trial of mp0317 (fap x cd40) monotherapy in patients with advanced solid tumors at the 2023 asco annual meeting

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation...

May 25, 2023, 5:01 pm

Cullinan oncology to present first monotherapy clinical data for cln-619, a novel anti-mica/b antibody, at asco 2023

CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose ca...

May 25, 2023, 5:00 pm

Geron's data allows development of several catalysts

Primary endpoint of 8-week transfusion independence met in the phase 3 IMerge study; Imetelstat was used as a ...

January 9, 2023, 7:01 pm

Applied molecular transport announces top-line phase 2 results from lombard monotherapy trial of oral amt-101 in patients with moderate-to-severe ulcerative colitis

– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to pla...

December 22, 2022, 10:30 pm

Agenus: advancement of botensilimab could create a great pivot point

Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy again...

December 13, 2022, 5:57 am

Vincerx pharma presents preclinical data on vip943 in acute myeloid leukemia models at the 64th american society of hematology annual meeting 2022

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with sign...

December 11, 2022, 3:05 pm

Fate therapeutics highlights ipsc-derived, off-the-shelf car nk cell programs for multiple myeloma at 2022 ash annual meeting

Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as ...

December 10, 2022, 7:46 pm

Rapt therapeutics presents update from its phase 1/2 clinical trial for flx475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer

Data Presented at ESMO Immuno-Oncology Congress SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT)...

December 8, 2022, 11:30 am

Rapt therapeutics to present flx475 phase 1/2 data at the european society for medical oncology (esmo) immuno-oncology annual congress

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s...

November 30, 2022, 7:05 pm

Achilles therapeutics to present early proof of concept of safety and clinical activity of clonal neoantigen reactive t cells at the esmo immuno-oncology annual congress 2022

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT ...

November 30, 2022, 6:05 pm

Rbc says verastem interim analysis in ovarian cancer reinforces enthusiasm

With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 progr...

June 7, 2022, 2:35 pm

Curis shares gain on encouraging data presentation from blood cancer trials at asco meeting

Curis Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical On...

June 6, 2022, 8:01 am

Immunogen's stock is up 12% after the fda accepts application for new ovarian-cancer therapy

Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an ...

May 23, 2022, 7:59 am


Search within

Pages Search Results: